IX Biopharma Ltd - ESG Rating & Company Profile powered by AI
Alternative corporations in the rating industry group for IX Biopharma Ltd are shown below. Browse to the bottom of this page for potential risks for IX Biopharma Ltd based on industry, location and size. If you are employed by IX Biopharma Ltd and you wish to licence your ESG rating, please contact us.
IX Biopharma Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.3; made up of an environmental score of 8.0, social score of 8.0 and governance score of 6.0.
7.3
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
160 | YungShin Global Holding Corp | 7.5 | High |
160 | Zentiva SA | 7.5 | High |
191 | IX Biopharma Ltd | 7.3 | High |
191 | Cellectis SA | 7.3 | High |
191 | Aurinia Pharmaceuticals Inc | 7.3 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does IX Biopharma Ltd have an accelerator or VC vehicle to help deliver innovation?
Does IX Biopharma Ltd disclose current and historical energy intensity?
Does IX Biopharma Ltd report the average age of the workforce?
Does IX Biopharma Ltd reference operational or capital allocation in relation to climate change?
Does IX Biopharma Ltd disclose its ethnicity pay gap?
Does IX Biopharma Ltd disclose cybersecurity risks?
Does IX Biopharma Ltd offer flexible work?
Does IX Biopharma Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does IX Biopharma Ltd disclose the number of employees in R&D functions?
Does IX Biopharma Ltd conduct supply chain audits?
Does IX Biopharma Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does IX Biopharma Ltd conduct 360 degree staff reviews?
Does IX Biopharma Ltd disclose the individual responsible for D&I?
Does IX Biopharma Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does IX Biopharma Ltd disclose current and / or historical scope 2 emissions?
Does IX Biopharma Ltd disclose water use targets?
Does IX Biopharma Ltd have careers partnerships with academic institutions?
Did IX Biopharma Ltd have a product recall in the last two years?
Does IX Biopharma Ltd disclose incidents of discrimination?
Does IX Biopharma Ltd allow for Work Councils/Collective Agreements to be formed?
Has IX Biopharma Ltd issued a profit warning in the past 24 months?
Does IX Biopharma Ltd disclose parental leave metrics?
Does IX Biopharma Ltd disclose climate scenario or pathway analysis?
Does IX Biopharma Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does IX Biopharma Ltd disclose the pay ratio of women to men?
Does IX Biopharma Ltd support suppliers with sustainability related research and development?
Does IX Biopharma Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does IX Biopharma Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is IX Biopharma Ltd involved in embryonic stem cell research?
Does IX Biopharma Ltd disclose GHG and Air Emissions intensity?
Does IX Biopharma Ltd disclose its waste policy?
Does IX Biopharma Ltd report according to TCFD requirements?
Does IX Biopharma Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does IX Biopharma Ltd disclose energy use targets?
Does IX Biopharma Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does IX Biopharma Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for IX Biopharma Ltd
These potential risks are based on the size, segment and geographies of the company.
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, Europe, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. Its lead product candidate is Wafermine, a sublingual ketamine oral wafer for the treatment of acute moderate to severe pain, as well as for depression. The company also offers Xativa, a sublingual cannabidiol wafer for the treatment of anxiety, chronic pain, neuropathic pain, cancer pain, and insomnia; BnoX, a sublingual buprenorphine wafer for the management of moderate to severe pain; and Wafesil and Silcap for the treatment of male erectile dysfunction. In addition, it offers LumeniX, a sublingual glutathione wafer for skin brightening and immunity; WafeRest for the alleviating jetlag and promotion of sleep; and SL-NAD+ supplements product. Further, the company develops Dexmedetomidine for agitation in dementia patients; Dronabinol for chemotherapy induced nausea, vomiting, and anorexia associated with weight loss in patients with HIV/AIDS.; Apomorphine to treat the motor symptoms of Parkinson's Disease; and IXB-321, a vaccine delivery platform. Additionally, it promotes and markets nutritional and supplements products through pharmacies and health food shops, JD and Tmall e-commerce platforms in China, as well as through online store; develops and commercializes of nutraceutical products; and provides laboratory services. iX Biopharma Ltd. was incorporated in 2004 and is headquartered in Singapore.